About this Journal Submit a Manuscript Table of Contents
Journal of Skin Cancer
Volume 2013 (2013), Article ID 327150, 9 pages
http://dx.doi.org/10.1155/2013/327150
Review Article

Merkel Cell Carcinoma: Chemotherapy and Emerging New Therapeutic Options

Universitätsklinik für Dermatologie, AKH, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090 Wien, Austria

Received 25 July 2012; Accepted 10 December 2012

Academic Editor: Boban M. Erovic

Copyright © 2013 Laura Desch and Rainer Kunstfeld. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Heath, N. Jaimes, B. Lemos et al., “Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features,” Journal of the American Academy of Dermatology, vol. 58, no. 3, pp. 375–381, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. U. Meyer-Pannwitt, K. Kummerfeldt, P. Boubaris, and J. Caselitz, “Merkel cell tumor or neuroendocrine skin carcinoma,” Langenbecks Archiv für Chirurgie, vol. 382, no. 6, pp. 349–358, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Lyhne, J. Lock-Andersen, K. Dahlstrøm et al., “Rising incidence of Merkel cell carcinoma,” Journal of Plastic Surgery and Hand Surgery, vol. 45, no. 6, pp. 274–280, 2011.
  4. M. Agelli, L. X. Clegg, J. C. Becker, and D. E. Rollison, “The etiology and epidemiology of merkel cell carcinoma,” Current Problems in Cancer, vol. 34, no. 1, pp. 14–37, 2010.
  5. B. D. Lemos, B. E. Storer, J. G. Iyer et al., “Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system,” Journal of the American Academy of Dermatology, vol. 63, no. 5, pp. 751–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. E. A. Engels, M. Frisch, J. J. Goedert, R. J. Biggar, and R. W. Miller, “Merkel cell carcinoma and HIV infection,” Lancet, vol. 359, no. 9305, pp. 497–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Lanoy, D. Costagliola, and E. A. Engels, “Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults,” International Journal of Cancer, vol. 126, no. 7, pp. 1724–1731, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. American Joint Committee on Cancer, “Merkel cell carcinoma,” in AJCC Cancer Staging Handbook, pp. 377–386, Springer, New York, NY, USA, 2010.
  9. J. P. Duprat, G. Landman, J. V. Salvajoli, and E. R. Brechtbühl, “A review of the epidemiology and treatment of Merkel cell carcinoma,” Clinics, vol. 66, no. 10, pp. 1817–1823, 2011. View at Publisher · View at Google Scholar
  10. J. C. Becker, “Merkel cell carcinoma,” Annals of Oncology, vol. 21, supplement 7, pp. vii81–vii85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Toker, “Trabecular carcinoma of the skin,” Archives of Dermatology, vol. 105, no. 1, pp. 107–110, 1972. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Steinstraesser, M. Kueckelhaus, and V. Koljonen, “Recent update on tumour biology and treatment of merkel cell carcinoma,” Handchirurgie Mikrochirurgie Plastische Chirurgie, vol. 43, no. 6, pp. 345–349, 2011 (German).
  13. V. Koljonen, “Merkel cell carcinoma,” World Journal of Surgical Oncology, vol. 4, article 7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. W. J. McAfee, C. G. Morris, C. M. Mendenhall, J. W. Werning, N. P. Mendenhall, and W. M. Mendenhall, “Merkel cell carcinoma: treatment and outcomes,” Cancer, vol. 104, no. 8, pp. 1761–1764, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Poulsen, D. Rischin, E. Walpole et al., “High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study—TROG 96:07,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4371–4376, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. T. K. George, P. A. di Sant'agnese, and J. M. Bennett, “Chemotherapy for metastatic Merkel cell carcinoma,” Cancer, vol. 56, no. 5, pp. 1034–1038, 1985. View at Scopus
  17. J. Redmond III, J. Perry, P. Sowray, S. J. Vukelja, and N. Dawson, “Chemotherapy of disseminated merkel-cell carcinoma,” American Journal of Clinical Oncology, vol. 14, no. 4, pp. 305–307, 1991. View at Scopus
  18. M. Azagury, B. Chevallier, D. Atlan, Y. Graic, J. P. Dayot, and E. Thomine, “VP-16, cisplatin, doxorubicin, and bleomycin in metastatic Merkel cell carcinoma. Report of a case with long-term remission,” American Journal of Clinical Oncology, vol. 16, no. 2, pp. 102–104, 1993. View at Scopus
  19. E. Bajetta, L. Rimassa, C. Carnaghi et al., “5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors,” Cancer, vol. 83, no. 2, pp. 372–378, 1998. View at Publisher · View at Google Scholar
  20. T. Y. Eng, M. G. K. Boersma, C. D. Fuller, S. X. Cavanaugh, F. Valenzuela, and T. S. Herman, “Treatment of merkel cell carcinoma,” American Journal of Clinical Oncology, vol. 27, no. 5, pp. 510–515, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Y. Eng, M. Naguib, C. D. Fuller, W. E. Jones III, and T. S. Herman, “Treatment of recurrent merkel cell carcinoma: an analysis of 46 cases,” American Journal of Clinical Oncology, vol. 27, no. 6, pp. 576–583, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Veness, L. Perera, J. McCourt et al., “Merkel cell carcinoma: improved outcome with adjuvant radiotherapy,” ANZ Journal of Surgery, vol. 75, no. 5, pp. 275–281, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Voog, P. Biron, J. P. Martin, and J. Y. Blay, “Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma,” Cancer, vol. 85, no. 12, pp. 2589–2595, 1999. View at Publisher · View at Google Scholar
  24. P. J. Allen, W. B. Bowne, D. P. Jaques, M. F. Brennan, K. Busam, and D. G. Coit, “Merkel cell carcinoma: prognosis and treatment of patients from a single institution,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2300–2309, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Wobser, N. Kürzinger, S. Ugurel, E. B. Bröcker, and J. C. Becker, “Therapy of metastasized Merkel cell carcinoma with liposomal doxorubicin in combination with radiotherapy,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 7, no. 6, pp. 521–525, 2009 (German).
  26. M. Schlaak, T. Podewski, W. Von Bartenwerffer et al., “Induction of durable responses by oral etoposide monochemotherapy in patients with metastatic Merkel cell carcinoma,” European Journal of Dermatology, vol. 22, no. 2, pp. 187–191, 2012.
  27. P. T. H. Tai, E. Yu, E. Winquist et al., “Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases,” Journal of Clinical Oncology, vol. 18, no. 12, pp. 2493–2499, 2000. View at Scopus
  28. M. Davids, A. Charlton, S. S. Ng et al., “Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic merkel cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 26, pp. e97–e100, 2009, Erratum in: Journal of Clinical Oncology, vol. 28, no. 18, p. 3098, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. W. E. Samlowski, J. Moon, R. J. Tuthill et al., “A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331),” American Journal of Clinical Oncology, vol. 33, no. 5, pp. 495–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. di Bartolomeo, E. Bajetta, R. Buzzoni et al., “Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group,” Cancer, vol. 77, no. 2, pp. 402–408, 1996.
  31. G. Meier, C. Waldherr, R. Herrmann, H. Maecke, J. Mueller-Brand, and M. Pless, “Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma: a case report,” Oncology, vol. 66, no. 2, pp. 160–163, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Fakiha, P. Letertre, J. P. Vuillez, and J. Lebeau, “Remission of Merkel cell tumor after somatostatin analog treatment,” Journal of Cancer Research and Therapeutics, vol. 6, no. 3, pp. 382–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. H. Shah, K. A. Varker, M. Collamore et al., “G3139 (Genasense) in patients with advanced merkel cell carcinoma,” American Journal of Clinical Oncology, vol. 32, no. 2, pp. 174–179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Jouary, C. Leyral, B. Dreno et al., “Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study,” Annals of Oncology, vol. 23, no. 4, pp. 1074–1080, 2012.
  35. E. Migliano, C. Monarca, M. Tedesco, M. I. Rizzo, and S. Bucher, “Merkel cell carcinoma and sentinel lymph node dissection: nine cases report,” Il Giornale di Chirurgia, vol. 29, no. 1-2, pp. 28–32, 2008 (Italian). View at Scopus
  36. D. Schrama, S. Ugurel, and J. C. Becker, “Merkel cell carcinoma: recent insights and new treatment options,” Current Opinion in Oncology, vol. 24, no. 2, pp. 141–149, 2012. View at Publisher · View at Google Scholar
  37. J. Becker, C. Mauch, R. D. Kortmann et al., “Short German guidelines: Merkel cell carcinoma,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 6, supplement 1, pp. S15–S16, 2008 (German). View at Scopus
  38. S. Pilotti, F. Rilke, and L. Lombardi, “Neuroendocrine (Merkel cell) carcinoma of the skin,” American Journal of Surgical Pathology, vol. 6, no. 3, pp. 243–254, 1982. View at Scopus
  39. R. K. Sibley, J. Rosai, E. Foucar, L. P. Dehner, and G. Bosl, “Neuroendocrine (Merkel cell) carcinoma of the skin. A histologic and ultrastructural study of two cases,” American Journal of Surgical Pathology, vol. 4, no. 3, pp. 211–221, 1980. View at Scopus
  40. J. B. Taxy, D. S. Ettinger, and M. D. Wharam, “Primary small cell carcinoma of the skin,” Cancer, vol. 46, no. 10, pp. 2308–2311, 1980. View at Scopus
  41. M. H. Kroll and C. Toker, “Trabecular carcinoma of the skin: further clinicopathologic and morphologic study,” Archives of Pathology and Laboratory Medicine, vol. 106, no. 8, pp. 404–408, 1982. View at Scopus
  42. S. V. Pollack and J. B. Goslen, “Small-cell neuroepithelial tumor of skin. A Merkel-cell neoplasm?” Journal of Dermatologic Surgery and Oncology, vol. 8, no. 2, pp. 116–122, 1982. View at Scopus
  43. P. J. Allen, Z. F. Zhang, and D. G. Coit, “Surgical management of Merkel cell carcinoma,” Annals of Surgery, vol. 229, no. 1, pp. 97–105, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. E. R. Kokoska, M. S. Kokoska, B. T. Collins, D. R. Stapleton, and T. P. Wade, “Early aggressive treatment for merkel cell carcinoma improves outcome,” American Journal of Surgery, vol. 174, no. 6, pp. 688–693, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Henness and P. Vereecken, “Management of Merkel tumours: an evidence-based review,” Current Opinion in Oncology, vol. 20, no. 3, pp. 280–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. M. T. Fernández-Figueras, L. Puig, E. Musulén et al., “Expression profiles associated with aggressive behavior in Merkel cell carcinoma,” Modern Pathology, vol. 20, no. 1, pp. 90–101, 2007. View at Publisher · View at Google Scholar
  47. H. Kukko, V. Koljonen, P. Lassus, E. Tukiainen, C. Haglund, and T. Böhling, “Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma,” Anticancer Research, vol. 27, no. 4C, pp. 2587–2589, 2007. View at Scopus
  48. R. V. Kartha and U. N. Sundram, “Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis,” Modern Pathology, vol. 21, no. 2, pp. 96–104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. B. L. Swick, L. Ravdel, J. E. Fitzpatrick, and W. A. Robinson, “Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate,” Journal of Cutaneous Pathology, vol. 35, no. 2, pp. 197–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Feinmesser, M. Halpern, E. Kaganovsky et al., “c-kit expression in primary and metastatic merkel cell carcinoma,” American Journal of Dermatopathology, vol. 26, no. 6, pp. 458–462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. L. D. Su, D. R. Fullen, L. Lowe, P. Uherova, B. Schnitzer, and R. Valdez, “CD117 (KIT receptor) expression in Merkel cell carcinoma,” American Journal of Dermatopathology, vol. 24, no. 4, pp. 289–293, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Strong, K. Shalders, R. Carr, and D. R. J. Snead, “KIT receptor (CD117) expression in Merkel cell carcinoma,” British Journal of Dermatology, vol. 150, no. 2, pp. 384–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. M. C. Heinrich, C. L. Corless, G. D. Demetri et al., “Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4342–4349, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. G. D. Demetri, M. von Mehren, C. D. Blanke et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” The New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Krasagakis, I. Fragiadaki, M. Metaxari et al., “KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro,” Journal of Cellular Physiology, vol. 226, no. 4, pp. 1099–1109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. A. G. Richetta, M. Mancini, A. Torroni et al., “Total spontaneous regression of advanced merkel cell carcinoma after biopsy: review and a new case,” Dermatologic Surgery, vol. 34, no. 6, pp. 815–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. J. C. Wooff, J. R. Trites, N. M. G. Walsh, and M. J. Bullock, “Complete spontaneous regression of metastatic merkel cell carcinoma: a case report and review of the literature,” American Journal of Dermatopathology, vol. 32, no. 6, pp. 614–617, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. K. G. Paulson, J. G. Iyer, A. R. Tegeder et al., “Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival,” Journal of Clinical Oncology, vol. 29, no. 12, pp. 1539–1546, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. S. M. Krishna and C. N. Kim, “Merkel cell carcinoma in a patient treated with adalimumab: case report,” Cutis, vol. 87, no. 2, pp. 81–84, 2011. View at Scopus
  60. S. P. Linn-Rasker, G. A. van Albada-Kuipers, S. V. Dubois, K. Janssen, and P. G. Zweers, “Merkel cell carcinoma during treatment with TNF-alpha inhibitors: coincidence or warning?” Nederlands Tijdschrift voor Geneeskunde, vol. 156, no. 22, article A4464, 2012 (Dutch).
  61. D. E. Rollison, A. R. Giuliano, and J. C. Becker, “New virus associated with Merkel cell carcinoma development,” Journal of the National Comprehensive Cancer Network, vol. 8, no. 8, pp. 874–880, 2010. View at Scopus
  62. H. Feng, M. Shuda, Y. Chang, and P. S. Moore, “Clonal integration of a polyomavirus in human Merkel cell carcinoma,” Science, vol. 319, no. 5866, pp. 1096–1100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Biver-Dalle, T. Nguyen, A. Touzé et al., “Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus,” Acta Oncologica, vol. 50, no. 3, pp. 479–480, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Houben, M. Shuda, R. Weinkam et al., “Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens,” Journal of Virology, vol. 84, no. 14, pp. 7064–7072, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Balducci, B. De Bari, S. Manfrida, G. R. D'Agostino, and V. Valentini, “Treatment of Merkel cell carcinoma with radiotherapy and imiquimod (Aldara): a case report,” Tumori, vol. 96, no. 3, pp. 508–511, 2010. View at Scopus
  66. D. Schrama, R. A. Reisfeld, and J. C. Becker, “Antibody targeted drugs as cancer therapeutics,” Nature Reviews Drug Discovery, vol. 5, no. 2, pp. 147–159, 2006. View at Publisher · View at Google Scholar · View at Scopus